Immunization schedules for the new human diploid cell vaccine against rabies.
Clinical and antibody responses of human volunteers to four different serial production lots of human diploid cell vaccine (HDCV) each with a different antigenic value are described. Three to four doses of HDCV administered over a period of 14 days produced high levels of virus neutralizing antibodies with an average titer up to 20 times higher than the titer elicited by four doses of duck embryo vaccine. Antibodies were still present one year after completion of vaccination. Only minimal differences in antibody response could be observed between groups receiving vaccines of different antigenic values. Untoward reactions to the vaccine were few. The possibility of using the vaccine as part of postexposure human prophylaxis against rabies is discussed.
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D000956:Antigens, Viral / Q000032:analysis; D002460:Cell Line; D004171:Diploidy; D004372:Ducks; D004625:Embryo, Nonmammalian; D006801:Humans; D007115:Immunization Schedule; D009500:Neutralization Tests; D011818:Rabies / Q000276:immunology / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000009:adverse effects; D011820:Rabies virus / Q000276:immunology
D000914:Antibodies, Viral; D000956:Antigens, Viral; D011819:Rabies Vaccines